Cingulate Inc CING

$4.76 +0.01 (0.21%)

Valuation

Market cap
69,220,000
Revenue TTM
$0
Net income TTM
$-22,450,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
52,600
Avg volume
124,118
Day's range
$4.70 – $4.90
Shares out
14,542,000
Stochastic %K
22%
Beta
-0.88
Analysts
Strong Sell
Price target
$21.20

Price

Company profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210...

Show more

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Industry
Biotechnology
Sector
Healthcare
Phone
913 942 2300
Website
https://www.cingulate.com
Address
1901 West 47th Place, Kansas City, United States

Latest news

Stocktwits

CARTE_BLANCHE_DEVEREAUX Oct 4, 10:42 PM
$ANRO $SLS $CING Is ThIs wHo YOu bULls cOnSIdeR... Stfu Yes. And I come with receipts @DarkH0rse91 Now... Into your proper place... *Slowly unzips*
0 replies
trader_jin_ Oct 2, 8:01 PM
$CING Waiting a bit longer is good news IMO, because it gives management more time to address everything at the factory and increases the chances that the resubmission receives a Class 1 review.
2 replies
Duke1979 Oct 2, 7:02 PM
$CING stay with it team. I know it's frustrating to wait. Hang in there!
0 replies
tarzzanman Oct 2, 8:00 AM
$CING volume is so low like wtf we need some positive news and more volume
0 replies
Gojaime69 Oct 2, 5:40 AM
$CING WATCHING PAINT DRY.
0 replies
Juhanialainen Oct 1, 4:12 AM
$VERA $CING $MAIA $BCTX $PYPD We are soft launching a comprehensive one-solution-to-cover-all-needs biotech investing service powerhouse — http://bioradar.io. This is BIG! The monthly price is insanely cheap, at least for now and you’ll get free 7 day trial to test it out risk free. I’m a partner in this 🇫🇮 based service as a Brand Ambassador & Senior Advisor and been involved in developing this service for the last few months in silence. Now the service is ready. We’ve built dozens of APIs to major data sources like Edgar for example for SEC filings, we have built-in PDUFA date calendar, dilution tracking, company cash situation, price volatility and social buzz alerts directly into your email and dozens of other features that a biotech investor needs. All in one place with just a few dollars per month. Check it out, try it free and let me know what you think?
1 replies
WhatGoesTrumpMustGoDown Sep 30, 7:22 PM
$CING Cing gonna Cing. one day we will see double digits, likely not till 2027.
0 replies
Jomppaaz Sep 30, 7:09 PM
$CING 🔥🔥
1 replies